FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208295890> ?p ?o ?g. }

• W3208295890 endingPage "4556" @default.
• W3208295890 startingPage "4546" @default.
• W3208295890 abstract "E5103 was a study designed to evaluate the efficacy and safety of bevacizumab. It was a negative trial for the end points of invasive disease-free survival and overall survival. The current work examines the tolerability of bevacizumab and other medication exposures with respect to clinical outcomes and patient-reported outcomes (PROs).Adverse events (AEs) collected from the Common Terminology Criteria for Adverse Events were summarized to form an AE profile at each treatment cycle. All-grade and high-grade events were separately analyzed. The change in the AE profile over the treatment cycle was delineated as distinct AE trajectory clusters. AE-related and any-reason early treatment discontinuations were treated as clinical outcome measures. PROs were measured with the Functional Assessment of Cancer Therapy-Breast + Lymphedema. The relationships between the AE trajectory and early treatment discontinuation as well as PROs were analyzed.More than half of all AEs (57.5%) were low-grade. A cluster of patients with broad and mixed AE (all-grade) trajectory grades was significantly associated with any-reason early treatment discontinuation (odds ratio [OR], 2.87; P = .01) as well as AE-related discontinuation (OR, 4.14; P = .001). This cluster had the highest count of all-grade AEs per cycle in comparison with other clusters. Another cluster of patients with primary neuropathic AEs in their trajectories had poorer physical well-being in comparison with a trajectory of no or few AEs (P < .01). A high-grade AE trajectory did not predict discontinuations.A sustained and cumulative burden of across-the-board toxicities, which were not necessarily all recognized as high-grade AEs, contributed to early treatment discontinuation. Patients with neuropathic all-grade AEs may require additional attention for preventing deterioration in their physical well-being." @default.
• W3208295890 created "2021-11-08" @default.
• W3208295890 creator A5014494071 @default.
• W3208295890 creator A5017739729 @default.
• W3208295890 creator A5024795182 @default.
• W3208295890 creator A5038425269 @default.
• W3208295890 creator A5039180386 @default.
• W3208295890 creator A5039323820 @default.
• W3208295890 creator A5044564476 @default.
• W3208295890 creator A5051051055 @default.
• W3208295890 creator A5068666503 @default.
• W3208295890 creator A5078129443 @default.
• W3208295890 creator A5079064611 @default.
• W3208295890 creator A5085875361 @default.
• W3208295890 creator A5090301769 @default.
• W3208295890 creator A5090808981 @default.
• W3208295890 date "2021-11-02" @default.
• W3208295890 modified "2023-10-12" @default.
• W3208295890 title "Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events" @default.
• W3208295890 cites W1964661764 @default.
• W3208295890 cites W1991312573 @default.
• W3208295890 cites W2077880074 @default.
• W3208295890 cites W2087202287 @default.
• W3208295890 cites W2103563357 @default.
• W3208295890 cites W2113246631 @default.
• W3208295890 cites W2118638289 @default.
• W3208295890 cites W2126275851 @default.
• W3208295890 cites W2126593985 @default.
• W3208295890 cites W2140103603 @default.
• W3208295890 cites W2142980017 @default.
• W3208295890 cites W2143015497 @default.
• W3208295890 cites W2153982924 @default.
• W3208295890 cites W2156635540 @default.
• W3208295890 cites W2160182926 @default.
• W3208295890 cites W2167224460 @default.
• W3208295890 cites W2314226163 @default.
• W3208295890 cites W2547100318 @default.
• W3208295890 cites W2750506302 @default.
• W3208295890 cites W2768023721 @default.
• W3208295890 cites W2883848636 @default.
• W3208295890 cites W2962764891 @default.
• W3208295890 cites W2998221352 @default.
• W3208295890 cites W3030609157 @default.
• W3208295890 cites W3087548584 @default.
• W3208295890 cites W4210527837 @default.
• W3208295890 doi "https://doi.org/10.1002/cncr.33992" @default.
• W3208295890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34726788" @default.
• W3208295890 hasPublicationYear "2021" @default.
• W3208295890 type Work @default.
• W3208295890 sameAs 3208295890 @default.
• W3208295890 citedByCount "2" @default.
• W3208295890 countsByYear W32082958902023 @default.
• W3208295890 crossrefType "journal-article" @default.
• W3208295890 hasAuthorship W3208295890A5014494071 @default.
• W3208295890 hasAuthorship W3208295890A5017739729 @default.
• W3208295890 hasAuthorship W3208295890A5024795182 @default.
• W3208295890 hasAuthorship W3208295890A5038425269 @default.
• W3208295890 hasAuthorship W3208295890A5039180386 @default.
• W3208295890 hasAuthorship W3208295890A5039323820 @default.
• W3208295890 hasAuthorship W3208295890A5044564476 @default.
• W3208295890 hasAuthorship W3208295890A5051051055 @default.
• W3208295890 hasAuthorship W3208295890A5068666503 @default.
• W3208295890 hasAuthorship W3208295890A5078129443 @default.
• W3208295890 hasAuthorship W3208295890A5079064611 @default.
• W3208295890 hasAuthorship W3208295890A5085875361 @default.
• W3208295890 hasAuthorship W3208295890A5090301769 @default.
• W3208295890 hasAuthorship W3208295890A5090808981 @default.
• W3208295890 hasBestOaLocation W32082958902 @default.
• W3208295890 hasConcept C121608353 @default.
• W3208295890 hasConcept C126322002 @default.
• W3208295890 hasConcept C143998085 @default.
• W3208295890 hasConcept C197934379 @default.
• W3208295890 hasConcept C207103383 @default.
• W3208295890 hasConcept C2776694085 @default.
• W3208295890 hasConcept C2777793932 @default.
• W3208295890 hasConcept C2777802072 @default.
• W3208295890 hasConcept C2778375690 @default.
• W3208295890 hasConcept C2778715236 @default.
• W3208295890 hasConcept C44249647 @default.
• W3208295890 hasConcept C530470458 @default.
• W3208295890 hasConcept C535046627 @default.
• W3208295890 hasConcept C71924100 @default.
• W3208295890 hasConceptScore W3208295890C121608353 @default.
• W3208295890 hasConceptScore W3208295890C126322002 @default.
• W3208295890 hasConceptScore W3208295890C143998085 @default.
• W3208295890 hasConceptScore W3208295890C197934379 @default.
• W3208295890 hasConceptScore W3208295890C207103383 @default.
• W3208295890 hasConceptScore W3208295890C2776694085 @default.
• W3208295890 hasConceptScore W3208295890C2777793932 @default.
• W3208295890 hasConceptScore W3208295890C2777802072 @default.
• W3208295890 hasConceptScore W3208295890C2778375690 @default.
• W3208295890 hasConceptScore W3208295890C2778715236 @default.
• W3208295890 hasConceptScore W3208295890C44249647 @default.
• W3208295890 hasConceptScore W3208295890C530470458 @default.
• W3208295890 hasConceptScore W3208295890C535046627 @default.
• W3208295890 hasConceptScore W3208295890C71924100 @default.
• W3208295890 hasFunder F4320337351 @default.
• W3208295890 hasIssue "24" @default.

• next